Solantel 50 mg/ml Oral Suspension for Sheep

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

Closantel

제공처:

Norbrook Laboratories Limited

ATC 코드:

QP52AG09

INN (International Name):

Closantel

복용량:

50 milligram(s)/millilitre

약제 형태:

Oral suspension

처방전 유형:

LM: Licensed Merchant as defined in relevant national legislation

치료 그룹:

Sheep

치료 영역:

closantel

치료 징후:

Endoparasiticide

승인 상태:

Authorised

승인 날짜:

2016-08-26

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Solantel 50 mg/ml Oral Suspension for Sheep
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml contains:
ACTIVE SUBSTANCE:
Closantel
50.0 mg
(as Closantel Sodium Dihydrate
54.375 mg)
EXCIPIENT(S):
Propylene glycol (E1520)
217.6 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oral suspension
Off-white to yellow suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Sheep
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of chronic and subacute fasciolosis (due to_
Fasciola hepatica_).
The product is effective against mature
and late immature flukes (from 5 weeks immature).
For the treatment of_ Oestrus ovis_ (Sheep Nasal Bot Fly)_._
For the treatment of inhibited, L4 and adult stages of_ Haemonchus
contortus_.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active
substance or to any of the excipients.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_6_
_/_
_0_
_8_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_1_
_4_
_6_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk of development of resistance and
could ultimately result in ineffective therapy:
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
Underdosing, which may be due to und